The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy

References

• Epilepsy Scotland. Available at: http://www.epilepsyscotland.org.uk [accessed 17 August 2006].
   Google Scholar
• Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256–1262
   PubMed Web of Science ®Google Scholar
• Epilepsy Action. Half of UK patients on epilepsy medication ‘still having seizures’. Available at: http://www.epilepsy.org.uk/news/archive/20040115.html [accessed 17 August 2006].
   Google Scholar
• Blais L, Sheehy O, St-Hilaire JM, et al. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. PharmacoEconomics 2005; 23: 493–503
   PubMed Web of Science ®Google Scholar
• van Hout BA, Gagnon DD, McNulty P, et al. The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation. PharmacoEconomics 2003; 21: 315–326
   PubMed Web of Science ®Google Scholar
• Ekman M, Forsgren L. Economic evidence in epilepsy: a review. European Journal of Health Economics 2004; 5((Suppl 1))S36–S42
   PubMedGoogle Scholar
• Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002; 43((Suppl 4))3–9
   PubMedGoogle Scholar
• Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41: 342–351
   PubMed Web of Science ®Google Scholar
• Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Research 1996; 23: 139–148
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics 1998; 13: 397–409
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31–41
   Web of Science ®Google Scholar
• Eisai Europe Ltd. Data on file. Eisai Europe Ltd. London, UK
   Google Scholar
• Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80–87
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236–242
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179–1186
   PubMed Web of Science ®Google Scholar
• Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2284–2291
   PubMed Web of Science ®Google Scholar
• Selai C, Trimble M, Price M, et al. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Current Medical Research and Opinion 2005; 21: 733–739
   PubMed Web of Science ®Google Scholar
• Guberman A, Neto W, Gassmann-Mayer C. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurologica Scandinavica 2002; 106: 183–189
   PubMed Web of Science ®Google Scholar
• General Register Office for Scotland. 2004 Annual review. Chapter 1-demographic overview. Available at: http://www.gro-scotland.gov.uk/statistics/library/annrep/rgs-annual-review-2004/chapter-1/index.html#Deaths [accessed 5 September 2006].
   Google Scholar
• Mohanraj R, et al. Presentation at the American Epilepsy Society 58th Annual Meeting; New Orleans, LA, December, 3–72004
   Google Scholar
• Nilsson L, Farahmand BY, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case–control study. Lancet 1999; 353: 888–893
   PubMed Web of Science ®Google Scholar
• Netten A, Curtis L. Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care 2003. The University of Kent, Canterbury, UK 2003
   Google Scholar
• Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998; 18: 281–296
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, London, UK 2004
   Google Scholar
• Remak E, Hutton J, Price M, et al. A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate. European Journal of Health Economics 2003; 4: 271–278
   PubMedGoogle Scholar
• Wilby J, Kainth A, McDaid C, et al. National Institute for Health and Clinical Excellence. Assessment report: a rapid and systematic review of the clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults. Available at: http://guidance.nice.org.uk/page.aspx?o=76399 [accessed 15 August 2007].
   Google Scholar